Arrowhead's Management Presents At 2012 Wedbush PacGrow Life Sciences Management Access Conference (Transcript)

Arrowhead Research Corporation (ARWR)

Wedbush PacGrow Life Sciences Management Access Conference Call

August 14, 2012 4:15 pm ET

Executives

Christopher Anzalone – President and Chief Executive Officer

Analysts

Presentation

Unidentified Analyst

So, we’re pleased to have Arrowhead Research here presenting at the Wedbush Life Sciences Management Access Conference. And let’s presenting for Arrowhead our Research Corporation, which is a public traded company focused on metabolic diseases or obesity another issues is Christopher Anzalone, CEO.

Christopher Anzalone

Thanks very much. All right, so Arrowhead is a targeted therapeutics company and we are focused entirely on gaining drugs, where they can be effective AnginaRex towards, those ends we have developed a number of platforms they enable us to target and to deliver multiple therapeutic mortalities. So we saw – we view these platforms in two primary asylums. One is we have the world largest human right peptide targeting library. This was developed at MD Anderson Cancer Center and we will talk about this in the next couple of slides.

We use these to conjugate the drugs to make peptide-drug conjugates or PDCs. Think of these as next generation antibody-drug conjugate or ADC. We also have extremely broad set of RNAi platforms. This was centered around delivery, but we also have broad premium to operate within RNAi chemistries.

These technologies came from a number of different areas primarily through the acquisition of Roche’s RNAi business back in October of 2011. We have a portfolio of delivery systems and however, we have two primary systems both of which are targetable, they are non-lipid. And so with those we can make targeted RNAi therapeutics. Now we can use those also in conjunction with our peptide library to make targeted – to which make peptide targeted RNAi therapeutics.

Now we are not just an IP company. We have substantial R&D facilities and capabilities. We got about a 24,000 square foot facility in Madison, Wisconsin where our R&D happens. This can also came into the Roche acquisition and what we have there is infrastructure of it that was build by big pharma and that the small biotech would have a very difficult time replicating. And so we have substantial capabilities there.

Unidentified Analyst

All right, so why should you care about this well. We are responding to four market opportunities. First, pharma launch to make their APIs better. We have over 42,000 targeting sequences that we can use to target. We think virtually any type of drug to make APIs better. We think we can shift the safety profile of the drug, as well as the efficacy profile of the drug by targeting with these peptides. Second, pharma launch in Richmond strategy what we mean by that is for example if the cancer drug has increased survival by two months, but that really means is that some patients will survive two years longer and some patients will survive two weeks longer. Of course, our goal is to drive the patients that will respond to the therapy into the therapy. We have the capabilities to do that by making companion diagnostics on the back of our targeting library as well.

Next, we want to make generics better. We really like the idea of the business of taking the generic with multiple years of clinical end markets history and targeting that generic to make it either safer end or more effective being as a good business and its really straightforward business.

And then finally of course Parma still needs a way to deliver siRNA, consistently and outside deliver and we have capabilities there as well. So we got multiple value creation points among these four areas and including developing drugs it will be partnered or licensed two foreseeable companies including allowing a foreseeable companies to build our platforms, yes.

Unidentified Analyst

Is the platform is in the skincare I thought lot was in the skincare?

Christopher Anzalone

In the skincare, we do not have any candidates in skincare at this time.

Unidentified Analyst

First of all, it’s ingredients in the skincare all the time, right?

Christopher Anzalone

Probably not exactly we’re talking about here. I go into that platform in the next few slides that’s an interesting question now. Okay, now we are not just a platform company, we are also a product company we have a fairly robust for these (inaudible) company product pipeline, for peptide-drug conjugates our PDCs our first candidate or first PDC is called a dipeptide its against obesity. We have begun in Phase I study at MD Anderson Cancer Center about a month ago and so we are dosing patients as we speak. We also have a generic conjugate program in oncology that we are developing that’s still preclinical with in targeted RNAi, we have CALAA-01, which is an oncology, it’s a solid tumor, RNAi therapeutic, we’re finishing the Phase Ib in the next couple of weeks. Our next RNAi therapeutics is called ARC-520 that is again hepatitis B and we believe that we can file an IND in the second quarter of 2013. And we also have follow-on programs within our RNAi program, RNAi platforms probably the most advanced is against renal cell carcinoma.

Now I’ve got these two hepatitis in ARC-520 because read we think that those are potentially attractive to partners early. And the reason is because they’re both serving or addressing large underserved markets, we got very [contaminant] preclinical data in both we got unique amount of action in both, and we’ll talk about that in next several slides. And the trials are designed to provide early efficacy signals in both of those.

Read the rest of this transcript for free on seekingalpha.com

If you liked this article you might like

Fed, Oil, Comcast and Boeing - 5 Things You Must Know Before the Market Opens

Fed, Oil, Comcast and Boeing - 5 Things You Must Know Before the Market Opens

Take a Look at These Stocks Poised to Trade Higher

Take a Look at These Stocks Poised to Trade Higher

These 5 Stocks Under $10 Could Explode Higher

These 5 Stocks Under $10 Could Explode Higher

Premarket Biotech Movers: Synergy, Arrowhead, BioCryst

Premarket Biotech Movers: Synergy, Arrowhead, BioCryst

These 3 Biotech Stocks Are Already Moving Wildly on Thursday

These 3 Biotech Stocks Are Already Moving Wildly on Thursday